DIRS.INFO The most relevant business & tech news

Three names in the industry – Johnson & Johnson , Merck and Bristol Myers Squibb – face a pivotal few weeks ahead. They join Bristol Myers Squibb CEO Chris Boerner, who agreed to the panel's initial invitation to appear. But why is the committee targeting Merck, J&J and Bristol Myers Squibb in the first place? J&J, Merck and Bristol Myers Squib are all suing to halt the talks, which will establish new prices that will go into effect in 2026. Bristol Myers Squibb's Opdivo is an immunotherapy used to treat cancers, including melanoma and lung cancer.

Persons: Annika Kim Constantino, – Johnson, Sen, Bernie Sanders, Joaquin Duato, Robert Davis, Chris Boerner, Sanders, Eli Lilly's, Januvia, Bristol Myers, He's, Biden, Merck's, Myers, Eliquis, Mike Perrone, it's Organizations: CNBC.com, Johnson, Merck, Bristol Myers Squibb, Bristol Myers, Medicare, Bristol, CNBC, pharma Locations: U.S, drugmakers

☆ Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
▼ + stars: | 2024-01-28 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +12 min

Bristol Myers Squibb's Eliquis is a blood thinner used to prevent clotting, to reduce the risk of stroke. Bristol Myers Squibb's Opdivo is an immunotherapy used to treat cancers, including melanoma and lung cancer. Investors will get updates on Merck and Bristol Myers Squibb's plans for the years ahead when they report earnings on Thursday and Friday, respectively. That's unlike generics, which are cheaper copycats of small-molecule drugs like Bristol Myers Squibb's Eliquis. Bristol Myers Squibb is also testing a new form of Opdivo, which is currently administered into a patient's veins.

Persons: Johnson, William Blair, Matt Phipps, Bristol Myers, Johnson's, Merck's Keytruda, J's Stelara, Opdivo, Phipps, biosimilars, Eliquis, Biosimilars, Humira, JB Reed, Samsung's, Piper Sandler, Christopher Raymond, AbbVie, Raymond, Chris Schott, Schott, Robert Davis, Keytruda, Davis, JPMorgan's Schott, Bristol Myers Squibb, George Frey, J, Amgen, J confidentially, Mike Perrone, It's, Anna Moneymaker Organizations: New York Stock Exchange, Johnson, NYSE Big, Bristol Myers Squibb, Merck, Biden, William Blair & Company, CNBC, Guggenheim, Bristol, Leerink Partners, Bloomberg, Getty, Bioepis, JPMorgan, JPMorgan Health Care, Moderna, Bristol Myers, Karuna Therapeutics, Hardy, Huntsman Cancer Institute, University of Utah, Reuters, Teva Pharmaceuticals, Pharma, U.S . Department of Health, Human Services Locations: drugmakers, EY, Europe, U.S, Cambridge , Massachusetts, Arda, EY's Americas, Bristol, Salt Lake City , Utah, Washington , DC

☆ Institutions Are (Quietly) Taking Sackler Money
▼ + stars: | 2024-01-25 | by ( Alex Marshall | ) www.nytimes.com time to read: +1 min

When arts organizations began shunning the Sackler family over its role in the U.S. opioid crisis, it wasn’t just American institutions that cut ties. Museums in Britain that had accepted Sackler largess were among the first to take action. After the National Portrait Gallery in London canceled a $1.3 million Sackler donation in 2019, the Tate museum group announced it would not seek any more of the family’s support. Other museums began discussing removing the Sackler name from their walls. According to the Sackler Trust’s latest accounts, which were published this month, the nonprofit committed around 5.2 million pounds, or $6.6 million, in 2022, comprising 66 grants to institutions.

Persons: Sackler, — Organizations: Museums, Tate, Sackler Trust —, Purdue Pharma, Sackler Locations: U.S, Britain, London, British

☆ Japan Business Leaders Return to China Seeking to Bolster Cooperation
▼ + stars: | 2024-01-24 | by ( Jan. | At P.M. | ) www.usnews.com time to read: +3 min

Japanese economic delegations had visited China every year since 1975, but those visits lapsed during the COVID-19 era when China largely shuttered its borders due to its stringent pandemic policies. During their visit this week, the Japanese business delegates, which included Masakazu Tokura, chairman of the powerful Keidanren, as the Japan Business Federation is known, are due to meet with Chinese Premier Li Qiang on Thursday. Japan is heavily reliant on China, where Japanese companies have for years invested in building manufacturing supply chains and forged relationships with local partners. China last year arrested a Japanese executive, an employee of the drugmaker Astellas Pharma, on suspicion of espionage. The move has had a chilling effect on business, Japanese officials say.

Persons: Masakazu Tokura, Premier Li Qiang, Fumio, Xi Jinping, Wang Yi, Gamble, Ryan Woo, Miyoung Kim, David Dolan, Michael Perry Organizations: Japan Business, Premier, Pharma, Procter, SK, Nidec Corp, Toyota, Nissan Locations: BEIJING, China, Japan, United States, Kishida, Greater China, Beijing, Singapore, Tokyo

☆ Stocks making the biggest moves premarket: Coinbase, TKO Group, United Airlines, D.R. Horton and more
▼ + stars: | 2024-01-23 | by ( Brian Evans | ) www.cnbc.com time to read: +5 min

The company sees earnings per share ranging between 60 and 65 cents, well below an LSEG estimate of 72 cents per share. Horton — Shares of the home construction company slipped more than 5% after first-quarter earnings per share missed Wall Street estimates. Horton earned $2.82 per share, while analysts polled by LSEG expected a profit of $2.88 per share. Analysts expected earnings of 80 cents per share, according to LSEG. Analysts expected a profit of $1.24 per share on revenue of $19.7 billion.

Persons: Truist, Enphase, Goldman Sachs, Glen Santangelo, D.R, Horton —, Horton, LSEG, Halliburton, FactSet's StreetAccount, groundings, Johnson — Johnson, Johnson, RTX, CNBC's Hakyung Kim, Samantha Subin, Jesse Pound, Lisa Kailai Han, Fred Imbert Organizations: JPMorgan, General Electric, Energy, Federal, 3M, Goldman, Teva Pharmaceutical Industries, pharma, Jefferies, Logitech —, Logitech, Wall Street, United Airlines –, United Airlines, LSEG, Boeing, Max, Barstool Sports, Netflix, Johnson, Verizon, Procter, Gamble, RTX Corporation, Wall

Tuesday's analyst calls include upgrades to two solar names and a downgrade to a key crypto stock. 7:05 a.m.: Citi increases Meta price target ahead of earnings Meta shares have more runway ahead, according to Citi. Analyst Kenneth Worthington downgraded the crypto exchange to underweight from neutral, reiterating his price target of $80. Analyst Jordan Levy upgraded Sunnova to buy from hold and raised his price target to $18 from $10. He upgraded Enphase Energy to buy from hold, moving his price target to $145 from $85.

Persons: Truist, Ronald Josey, Josey, — Pia Singh, TD Cowen, Jason Gabelman, Gabelman, Jefferies, Glen Santangelo, Teva, Cantor Fitzgerald, C.J, Muse, Kenneth Worthington, Worthington, Coinbase, — Fred Imbert, Jordan Levy, Levy Organizations: CNBC, Enphase Energy, Federal Reserve, JPMorgan, Citi, Meta, Exxon, Chevron, Cowen, Exxon Mobil, Teva Pharmaceuticals, Jefferies Investors, pharma, mdc, Nvidia, Energy, Sustainability Locations: buybacks, Teva, Monday's

☆ New York AG pushing for lifetime Trump ban cites Martin Shkreli ruling
▼ + stars: | 2024-01-23 | by ( Dan Mangan | ) www.cnbc.com time to read: +2 min

Martin Shkreli, former chief executive officer of Turing Pharmaceuticals AG, exits court in New York, US, on Wednesday, Oct. 4, 2023. What does former President Donald Trump have in common with "Pharma bro" Martin Shkreli? A penchant for harshly trolling their enemies online and an attorney general who wants both of them banned for life from their preferred business. The ruling stemmed from an antitrust lawsuit James, the Federal Trade Commission, and six other states filed against Shkreli. James, in that case, asked Judge Arthur Engoron to ban Trump for life from the New York real estate industry and to bar his sons, Donald Trump Jr. and Eric Trump, from that sector for five years, along with fining them $360 million.

Persons: Martin Shkreli, Donald Trump, Pharma bro, Letitia James's, James, Judge Arthur Engoron, Donald Trump Jr, Eric Trump, Engoron, Colleen Faherty Organizations: Turing Pharmaceuticals AG, Pharma, New York, Shkreli, Trump, U.S, Circuit, New York federal, Federal Trade Commission, New Locations: New York, Manhattan, Fed

☆ Appeals court upholds 'pharma bro' Martin Shkreli lifetime ban from drug industry
▼ + stars: | 2024-01-23 | by ( Dan Mangan | ) www.cnbc.com time to read: +4 min

A federal appeals court Tuesday upheld a lifetime ban on "pharma bro" Martin Shkreli from working in the pharmaceuticals industry as well as an order to pay up to $64.6 million in disgorged profits for blocking competition to the drug Daraprim. His lawyer, Benjamin Brafman, in a statement to CNBC on the appeals court decision, said, "The lifetime ban is too severe." In its eight-page ruling, the appeals court noted that Shkreli argued that Manhattan federal court Judge Denise Cote "abused" her discretion in imposing a lifetime ban on him from the drug business. "The district court found, and Shkreli does not dispute, that Shkreli's illegal scheme was "egregious, deliberate, repetitive, long-running, and ultimately dangerous." "Given his strategic decision in the district court, there is no injustice to Shkreli by us declining to address his new argument."

Persons: Martin Shkreli, pharma bro, Shkreli, Benjamin Brafman, Brafman, Denise Cote, —, Peluso Organizations: Turing Pharmaceuticals AG, pharma, U.S, Circuit, New, Federal Trade Commission, CNBC, FTC, Vyera Pharmaceuticals, Phoenixus, Mr Locations: New York, California, Manhattan

☆ Morgan Stanley likes biopharma as a defensive play — giving one stock 119% upside
▼ + stars: | 2024-01-22 | by ( Ganesh Rao | ) www.cnbc.com time to read: +3 min

The biopharmaceutical sector is expected to offer a safe haven from macroeconomic and earnings concerns ahead of final quarterly results from companies, according to Morgan Stanley. Morgan Stanley, however, cautioned that the outlook for drug pricing reform in the U.S. poses risks for the sector. Shares of Indivior , argenx , AstraZeneca , Merck , Lonza, Sweden's Sobi, Novo Nordisk and Sandoz Group were among those listed by Morgan Stanley with a "buy" rating. In a bull case where Sublocade hits $2.2 billion in sales by 2030, Morgan Stanley sees shares rising further to 3,500 British pence. Novo Nordisk Shares of Novo Nordisk , a leader in diabetes and obesity drugs, offer a 9.4% upside, according to Morgan Stanley.

Persons: Morgan Stanley, Mark D Purcell, Sweden's, Sublocade, Thibault Boutherin, Morgan, — CNBC's Michael Bloom Organizations: Barclays, Bank of America, AstraZeneca, Merck, Lonza, Novo Nordisk, Sandoz Group, AstraZeneca AstraZeneca, British pharma, EU Locations: U.S, argenx, Novo, Indivior

☆ Here's why a top VC says healthcare investors should make growth-stage bets right now — and where he's looking for those deals
▼ + stars: | 2024-01-18 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +5 min

As a multi-stage VC fund, Lightspeed has an advantage in its exposure to both early-stage and later-stage healthcare markets, Imanbayev said. And many later-stage healthcare startups still have plenty of room to grow, he said. The first one to three years are often slow-moving for a healthcare startup, too, as it works to get its first partnerships with payers or providers, he said. But they also tend to be less risky, since later-stage startups should have revenue streams or partnerships that demonstrate their value. Lightspeed led value-based care startup Aledade's $260 million Series F in June 2023, an unusually large deal as other investors cut much smaller checks.

Persons: —, Galym, Imanbayev, I'm, There's, Farzad Mostashari, Aledade Tom Sandner, VCs, Abridge, he's, Chris Severn Organizations: Business, Lightspeed Venture Partners, Lightspeed, CVS, Health, Turquoise Health, Pharma, FDA, pharma

☆ Top pharma CEO says preparedness for a new pandemic has not improved
▼ + stars: | 2024-01-17 | by ( Vicky Mckeever | ) www.cnbc.com time to read: 1 min

Vas Narasimhan, chief executive officer of Novartis AG, listens during a panel session on the opening day of the World Economic Forum (WEF) in Davos, Switzerland, on Tuesday, Jan. 22, 2019. Vas Narasimhan, CEO of pharmaceutical firm Novartis, told CNBC Tuesday that he didn't believe there had been much improvement in preparedness for pandemics in the wake of the Covid crisis. "I'm sad to say, I don't think we've improved unfortunately," said Narasimhan, speaking at the World Economic Forum in Davos, Switzerland. He explained that there did not appear to be the continued level of investment as hoped for, during this "inter-pandemic" period. "Now that we're past the pandemic — and really because of the feats of our industry, companies coming up with incredible mRNA vaccines and diagnostic tools — we're back to almost no investment from governments," Narasimhan said.

Persons: Vas, Narasimhan Organizations: Novartis AG, Economic, Novartis, CNBC Locations: Davos, Switzerland

☆ The weight loss drug market may soon get more crowded. Here are the companies trying to enter the booming space
▼ + stars: | 2024-01-17 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Michael Siluk | UCG | Getty ImagesBoehringer IngelheimBoehringer Ingelheim is developing a weight loss drug with Danish biotech firm Zealand Pharma. Some popular weight loss drugs such as Novo Nordisk's Wegovy only target GLP-1. Terns PharmaceuticalsSmaller drugmakers are developing their own weight loss drugs. Quirk acknowledged that it may be difficult for Terns to set its pill apart from other weight loss drugs. Viking Therapeutics expects to release mid-stage trial data on its weight loss injection in the first half of the year.

Persons: Michael Siluk, Boehringer Ingelheim, Erin Quirk, Quirk, it's, Eli Lilly's, Roger Song Organizations: UCG, Getty, Zealand Pharma, Nordisk's, Drug Administration, JPMorgan Healthcare Conference, Pharmaceuticals, Terns Pharmaceuticals, GLP, Viking Therapeutics, Therapeutics, Jefferies Locations: Viking

☆ Pharma could see a wave of M&A activity in 2024, says Jefferies' Michael Yee
▼ + stars: | 2024-01-16 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPharma could see a wave of M&A activity in 2024, says Jefferies' Michael YeeMichael Yee, Jefferies senior biotech analyst, joins 'Fast Money' to talk dealmaking in the pharma sector in 2024.

Persons: Jefferies, Michael Yee Michael Yee Organizations: Email Pharma, Jefferies, pharma

☆ 4 stock ideas I brought back from the JPMorgan Healthcare Conference and everything else I learned about the industry
▼ + stars: | 2024-01-15 | by ( Jim Cramer | ) www.cnbc.com time to read: +12 min

We will go over them – but first, let me talk about what I learned at last week's JPMorgan Health Care Conference that I attended in San Francisco, and what it means to your portfolio. We know health care has a lot of angles too it. The previous CEO Roz Brewer was from Starbucks and struggled with the role that Walgreens plays in health care. You have to be following the transformation of Bristol-Myers, which is opening its wallet to buy a host of drug companies, including anti-psychotic firm Karuna. Health care is the way to go.

Persons: Regeneron, Pfizer, Eli Lilly, Dave Ricks, Lilly, donanemab, Lilly's, Zepbound, it's, Abbott, It's, Roche, Merck, Myers, ABT, Robert Ford, Tim Wentworth, He's, Roz Brewer, Wentworth, he'll, Brewer wasn't, Bob Bradway, Amgen, Vas Narasimhan, Sandoz, Karuna, Medtronic, Hugo, Morgan Stanley, Wells, Covid, Cramer's, Jim Cramer, Jim, Las Vegas Brendan Smialowski Organizations: Abbott Labs, Covid, Novartis, Amgen, Walgreens Boots Alliance, JPMorgan Health Care Conference, Humana, Drug Administration, Novo Nordisk, Dickinson Co, Bristol, Myers Squibb, Pfizer, Department, WBA, Walgreens, Starbucks, -, pharma, Merck, Keytruda, Horizon Therapeutics, Federal Trade Commission, Myers, BD, CVS Health, JPMorgan, Cramer's Charitable, CNBC, Consumer, AFP, Getty Locations: San Francisco, GLP, North Carolina, Europe, Cencora, Amgen, West, Bristol, Target, Las Vegas

☆ Biotech and pharma companies are betting on a promising class of cancer drugs to drive growth
▼ + stars: | 2024-01-14 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

SAN FRANCISCO — An established but promising group of cancer drugs was a red-hot market in 2023, and more companies could look to the treatments to fuel growth in the year ahead. Interest in the drugs will only continue this year, as some analysts expect more dealmaking and advancements in ADCs currently in development. The drugs also have potential to draw huge profits: ADCs could account for $31 billion of the $375 billion worldwide cancer market in 2028, according to estimates from the drug market research firm Evaluate. The market for those drugs in 2023 was estimated to be worth around $9.7 billion, another report from research firm MarketsandMarkets said. Everyone wants to gain exposure to [ADCs] and basically make it a cornerstone of their entire corporate strategy," Hsieh told CNBC.

Persons: FRANCISCO —, Johnson, Andy Hsieh, William Blair, MarketsandMarkets, Hsieh Organizations: FRANCISCO, JPMorgan Healthcare Conference, ADC, Pfizer, Merck, William Blair & Company, CNBC Locations: San Francisco, ADCs, drugmakers, Asia

☆ What's old is new: Our 3 best stocks to start 2024 were also big winners last year
▼ + stars: | 2024-01-12 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +6 min

Artificial intelligence chipmaker Nvidia , cybersecurity provider Palo Alto Networks and pharma giant Eli Lilly are the Club's biggest gainers to start 2024. Palo Alto Networks, meanwhile, jumped nearly 112% last year, becoming the first cybersecurity company to reach a $100 billion market capitalization . LLY 3M mountain Eli Lilly 3 months Eli Lilly has been positive in six of the eight trading days in 2024, including Thursday's session . PANW 3M mountain Palo Alto Networks 3 months Shares of Palo Alto Networks began 2024 on a rough note, falling in each of the first four trading days amid a larger seven-session skid that stretched into December. Wednesday's advance came after Morgan Stanley hiked its Palo Alto price target to $375 per share from $304.

Persons: haven't, Eli Lilly, Wall, hasn't, Eli Lilly's, Oppenheimer, Lilly, Morgan Stanley, Jim Cramer's, Jim Cramer, Jim Organizations: Nvidia, Palo Alto Networks, pharma, Club, Palo, Consumer, Semiconductor, Mizuho, Truist, Bank of America, JPMorgan Healthcare Conference, CNBC, New York Stock Exchange, Bloomberg, Getty Locations: Palo Alto, Las Vegas, New York, U.S

☆ Zero knowledge proofs could 'fix the Internet' and make us all trust each other again, former Merck CIO says
▼ + stars: | 2024-01-10 | by ( Julie Bort | ) www.businessinsider.com time to read: +5 min

Read preview"I think we're at the cusp of changing the world," investor Clark Golestani said of a technology called Zero Knowledge Proofs. Golestani spent 24 years as a chief information officer at pharma giant Merck, before becoming a venture investor five years ago. He's an investor and board member of a startup named Toposware that hopes to embed ZKP security into its customers' everyday internet usage. It's a tech that Andreessen Horowitz crypto investor Michael Blau recently compared to a magician's trick. Toposware is developing a cloud service, a so-called "settlement layer" where companies can add its ZKP service to their networks.

Persons: —, Clark Golestani, Golestani, Theo Gauthier —, Taher Elgamal, Andreessen Horowitz, Michael Blau, Blau, Toposware, Gauthier Organizations: Service, pharma, Merck, Netscape Communications, Business, Stanford, CEA, French Atomic Energy Commission Locations: Toposware, Europe, United States

☆ Getting hot new weight-loss drugs like Wegovy will still be a struggle in 2024
▼ + stars: | 2024-01-04 | by ( ) www.businessinsider.com time to read: +11 min

AdvertisementIf you were hoping that powerhouse weight-loss drugs like Wegovy would be easier to get in 2024, you may be disappointed. Don't expect Medicare coverage any time soonMedicare could play a major role in expanding coverage of weight-loss drugs . Americans' hunger for weight-loss drugs, and the shockwaves it's likely to send through the culture and economy, are only just beginning. He oversees the state employee health plan, which saw costs skyrocket as thousands of workers suddenly started taking weight-loss drugs. People who are already getting weight-loss drugs will be able to keep taking them.

Persons: —, Renee Rayburg, Mercer, Eli Lilly's, Jose Luis Pelaez, there's, Wegovy, Bill Coyle, ZS, Eli Lilly, David Risinger, Lilly, Risinger, Morgan Stanley, Mounjaro, They're, That's, Patrik Jonsson, Lilly USA, Coyle, Dale Folwell, Folwell Organizations: Service, Pharmaceutical, Group, Novo Nordisk's Wegovy, Mayo Clinic, University of Texas, Hennepin Healthcare, Medicare, Capital Alpha Partners, Vanderbilt University, Nordisk's Wegovy, Novo Nordisk, pharma, Nordisk's, FDA, Pharma, UBS BioPharma Conference, Walmart, Jefferies, Nordisk Locations: Mounjaro, Government, Minnesota, Minneapolis, Hennepin, ZS, U.S, Carolina, North Carolina

☆ Pharma giants are hiking prices on over 500 drugs for 2024, report says
▼ + stars: | 2024-01-02 | by ( Rebecca Rommen | ) www.businessinsider.com time to read: +1 min

Read previewPharmaceutical giants Pfizer, Sanofi, and Takeda Pharmaceutical are due to raise prices on more than 500 drugs in the US from January, according to the Reuters news agency. This story is available exclusively to Business Insider subscribers. It comes as the pharmaceutical sector prepares for the Biden Administration's release of discounted prices for 10 high-cost drugs in September. AdvertisementFurther in the future, the Biden administration's Inflation Reduction Act includes new provisions to allow the government's Medicaid health program to directly negotiate drug prices with their makers — but only from 2026. It said that three companies, including GlaxoSmithKline, are poised to lower prices in January across at least 15 drugs.

Persons: —, Takeda, Biden Organizations: Service, Pfizer, Sanofi, Takeda Pharmaceutical, Reuters, Business, Biden, GlaxoSmithKline

☆ Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
▼ + stars: | 2023-12-28 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. "We expect this environment to continue but look forward to the prospect of lower interest rates in 2024." When that happens, Canaccord Genuity said to expect a "strong rally across the biotech sector rewarding innovative, but riskier assets." Analysts have said the rich price reflects the opportunity for ImmunoGen's Elahere cancer treatment , which has quickly established itself as the standard of care for types of ovarian cancer. 'Oversold and cheap' In a research note Friday, Jefferies analyst Michael Yee said "a significant short squeeze" was helping biotech stocks in the fourth quarter.

Persons: Dan Lyons, Janus Henderson, John Newman, Canaccord Genuity, Janus, Lyons, Bristol Myers Squibb, Karuna, AstraZeneca, Eli Lilly, AbbVie, Jonathan Miller, Miller, bode, Jonathan Krinsky, Krinsky, BTIG's, Jefferies, Michael Yee, Yee, NASH, Madrigal, we're, David Risinger, — CNBC's Michael Bloom Organizations: Drug, Federal, Bristol Myers, Karuna Therapeutics, CART, Bristol Myers Squibb, Cerevel Therapeutics, Securities and Exchange Commission, pharma, P Biotech, Nasdaq Biotech, Apogee Therapeutics, Madrigal Pharmaceuticals, Madrigal, resmetirom, Vertex Pharmaceuticals, Leerink Partners Locations: ImmunoGen

☆ Oprah's flip on weight loss drugs is a sign of what's to come for the 'Ozempic trade' in 2024
▼ + stars: | 2023-12-25 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +10 min

Lilly's Zepbound recently entered the weight loss market, and is off to a strong start. But what's ahead for the weight loss trade in 2024? Beyond weight loss One of 2023's most pivotal events in the space was Novo Nordisk's release of top line results from its Select trial in August . In 2023, the exuberance around weight loss drugs roiled markets in many unexpected ways. The affected companies have also been very vocal in addressing how they plan to coexist with these weight loss products.

Persons: Oprah Winfrey, Eli Lilly, they've, Lilly's, Lilly's Zepbound, Andy Acker, Janus Henderson's, Lilly, Novo, FactSet, Acker, Janus, Buzz, Gregory Renza, Renza, Goldman Sachs, Chris Shibutani, Mike Kratky, Kratky, Dexcom, Leerink, Winfrey, I've, Winfrey's, Michael Bloom Organizations: Novo Nordisk, Wall Street, Wall, RBC Capital, Pfizer, Structure Therapeutics, AstraZeneca, Leerink, Nestle, Oprah Daily, Winfrey, International Locations: Friday's, Eccogene, MedTech, 3Q23

☆ See the 20-slide pitch deck that got Merck to back an AI-powered biotech creating drugs for untreatable diseases
▼ + stars: | 2023-12-14 | by ( Rebecca Torrence | ) www.businessinsider.com time to read: +1 min

Pepper Bio wants to reduce those costs by getting drug developers to the right targets faster, using what it calls a "transomics" approach. Pepper Bio also looks at protein phosphorylation, an indication of how and when proteins are active. Pepper Bio CEO Jon Hu said working with Merck gave the startup insight into the needs of the pharma firms to which Pepper Bio hopes to sell its software. "It allows us to understand, truthfully, what drug developers are struggling with," he said. Here's the 20-slide pitch deck that got Pepper Bio $6.5 million in seed funding.

Persons: Pepper, Pepper Bio's cofounders, Jon Hu Organizations: Business, NFX, Silverton Partners, Mana Ventures, Tensility Ventures, VSC Ventures, Merck, Merck Digital Sciences, pharma

download the appSign up to get the inside scoop on today’s biggest stories in markets, tech, and business — delivered daily. In a 15-second video released to YouTube on Wednesday night, President Joe Biden promised the move would lower prices. It's the latest health policy pitch from a White House gearing up to make its efforts to tackle drug prices a central theme in next year's reelection campaign. Pharmaceutical companies have pushed back on the idea that prices alone are enough for Washington to act against a drug's patent. The plan could threaten future drugs, according to the pharmaceutical lobbying firm Pharmaceutical Research and Manufacturers of America, or PhRMA.

Persons: —, Biden, Joe Biden, Elizabeth Warren of Massachusetts, Amy Klobuchar, Neera Tanden, Megan Van Etten, William Pierce, George W, Pierce Organizations: Service, Business, YouTube, White, Medicare, Health, Human Services, Pharmaceutical, Pharmaceutical Research, Manufacturers of America, HHS Locations: WASHINGTON, Sens, Minnesota, Washington

☆ Eli Lilly vs. Novo Nordisk: The pros deliver their verdict on the viral weight-loss stocks
▼ + stars: | 2023-12-06 | by ( Amala Balakrishner | ) www.cnbc.com time to read: +4 min

It has been quite a year for both Eli Lilly and Novo Nordisk given the boom in weight-loss drugs. Shares in Eli Lilly are up around 60% year-to-date, while its Danish counterpart Novo Nordisk has seen a gain of around 50%. At present, both Eli Lilly and Novo Nordisk offer weight loss treatments. Novo Nordisk Novo Nordisk's Wegovy recently made headlines for reducing the risk of heart attacks and strokes by 20% in adults with heart disease and obesity. Aside from Eli Lilly and Novo Nordisk, Pfizer , Johnson & Johnson and AstraZeneca are also developing weight-loss drugs.

Persons: Eli Lilly, Stocks, Rahul Ghosh, Rowe Price, TRP's Ghosh, Eli Lilly's, Ghosh, FactSet, Lilly, Novo Nordisk Novo Nordisk's Wegovy, Elizabeth Field, Squawk, What's, it's, Michael Bloom Organizations: Novo Nordisk, Nordisk, CNBC Pro, U.S . Food, Administration, pharma, Novo Nordisk Novo Nordisk's, Heart Association Scientific, Citi, Pfizer, Johnson, AstraZeneca, Barclays Locations: Danish, U.S, Novo

☆ Supreme Court Weighs Purdue Pharma’s $6 Billion Opioid Settlement
▼ + stars: | 2023-12-05 | by ( Jess Bravin | ) www.wsj.com time to read: +1 min

Purdue Pharma headquarters in 2019; a Purdue lawyer said in court Monday that if a settlement with the company didn’t go forward, opioid-crisis victims might not see compensation. Photo: timothy a. clary/Agence France-Presse/Getty ImagesWASHINGTON—Supreme Court justices wrestled Monday with the uncomfortable bargain struck between most victims of the opioid crisis and the Sackler family, whose Purdue Pharma promoted the addictive painkiller OxyContin: providing timely compensation for survivors in exchange for granting the wealthy family immunity from future civil lawsuits. That settlement was reached before a bankruptcy judge and approved in May by a federal appeals court in New York. It would see the Sacklers pay $6 billion to individual victims and state governments in exchange for eliminating potential liability for additional claims, such as fraud—even though they, unlike Purdue, haven’t sought bankruptcy protection. The deal was made under a catchall provision of federal law authorizing bankruptcy judges to issue orders and judgments that may be “necessary or appropriate” to resolve cases.

Persons: timothy, clary, Sackler, haven’t Organizations: Purdue Pharma, Purdue, Agence France, Getty, WASHINGTON Locations: New York

Search resuls for: "PHARMA"

25 mentions found